Publication:

Rapid generation of novel models of RAG1 deficiency by CRISPR/Cas9-induced mutagenesis in murine zygotes

Loading...
Thumbnail Image

Open/View Files

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

de Bruin, Lisa Ott, Wei Yang, Kelly Capuder, Yu Nee Lee, Maddalena Antolini, Robin Meyers, Martin Gellert, Kiran Musunuru, John Manis, and Luigi Notarangelo. 2016. “Rapid generation of novel models of RAG1 deficiency by CRISPR/Cas9-induced mutagenesis in murine zygotes.” Oncotarget 7 (11): 12962-12974. doi:10.18632/oncotarget.7341. http://dx.doi.org/10.18632/oncotarget.7341.

Abstract

Mutations in the Recombination Activating Gene 1 (RAG1) can cause a wide variety of clinical and immunological phenotypes in humans, ranging from absence of T and B lymphocytes to occurrence of autoimmune manifestations associated with expansion of oligoclonal T cells and production of autoantibodies. Although the mechanisms underlying this phenotypic heterogeneity remain poorly understood, some genotype-phenotype correlations can be made. Currently, mouse models of Rag deficiency are restricted to RAG1−/− mice and to knock-in models carrying severe missense mutations. The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system is a novel and powerful gene-editing strategy that permits targeted introduction of DNA double strand breaks with high efficiency through simultaneous delivery of the Cas9 endonuclease and a guide RNA (gRNA). Here, we report on CRISPR-based, single-step generation and characterization of mutant mouse models in which gene editing was attempted around residue 838 of RAG1, a region whose functional role had not been studied previously.

Description

Research Data

Keywords

recombination activation gene 1, RAG1, genome editing, immunodeficiency, CRISPR/Cas9

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories